Global Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Regional Forecasts 2022-2032

Description

The global pancreatic cancer precision medicine market was valued at USD 551.01 million in 2023 and is projected to reach USD 2676.98 Million by 2032, expanding at a CAGR of 19.2% from 2024 to 2032. The growing demand for targeted therapies, immunotherapies, and biomarker-driven treatment strategies is significantly enhancing survival rates while minimizing treatment-related side effects. The increasing adoption of next-generation sequencing (NGS), molecular diagnostics, and liquid biopsy technologies is transforming pancreatic cancer detection and treatment by enabling personalized medicine approaches tailored to individual patient profiles.

The rising incidence of pancreatic cancer, driven by an aging population and lifestyle-related factors, is accelerating market demand. According to Cancer Australia, 4,641 new pancreatic cancer cases were diagnosed in 2024. The demand for innovative precision treatments is surging as pharmaceutical companies, biotech firms, and research institutions expand their efforts in clinical trials and drug discovery. Regulatory agencies such as the FDA and EMA have introduced fast-track approvals for precision medicine therapies, expediting the commercialization of novel treatments.

Among the therapeutic approaches, targeted therapy dominated the market in 2024, accounting for a 56.0% share. The rising adoption of monoclonal antibodies, PARP inhibitors, and KRAS/EGFR inhibitors has facilitated genetic mutation-based treatment selection. Meanwhile, immunotherapy, which includes immune checkpoint inhibitors (PD-1/PD-L1 inhibitors), cancer vaccines, and CAR-T therapies, is gaining traction due to its potential for long-term remission. Additionally, chemotherapy-precision combinations are projected to witness the fastest CAGR of 20.3% from 2025 to 2030, as they offer enhanced tumor-targeting capabilities through molecular profiling.

Regionally, North America led the market in 2024, with a revenue share of 42.9%, driven by advanced oncology research, robust healthcare infrastructure, and significant investments in genomic profiling. The U.S. pancreatic cancer precision medicine market accounted for 81.4% of the North American revenue share, benefiting from government research funding, increasing adoption of biomarker-based diagnostics, and strong regulatory support. Europe and Asia Pacific are also emerging as promising regions, with Asia Pacific expected to register the fastest CAGR of 6.1%, supported by growing cancer awareness, improving healthcare infrastructure, and rising clinical trial activity in countries such as Japan, China, and India.

Major Market Players Included in this Report:

AstraZeneca
Pfizer Inc.
Novartis AG
Amgen Inc.
F. Hoffmann-La Roche Ltd
Bayer AG
Eli Lilly and Company
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd
PharmaCyte Biotech, Inc.
Genentech, Inc.
Guardant Health
Illumina, Inc.
Thermo Fisher Scientific Inc.
FOUNDATION MEDICINE, INC.

The Detailed Segments and Sub-Segments of the Market Are Explained Below:

By Therapeutic Approach:

Targeted Therapy
- PARP Inhibitors
- Monoclonal Antibodies
- Small Molecule Inhibitors (EGFR Inhibitors, KRAS Inhibitors)
Immunotherapy
- Immune Checkpoint Inhibitors (PD-1 Inhibitors, PD-L1 Inhibitors)
- Cancer Vaccines (GVAX, Algenpantucel-L)
- Adoptive T-Cell Therapies (CAR-T Therapies)
Chemotherapy-Precision Combinations
Other Therapeutic Approaches

By Diagnostic Technology:

Genomic Testing
Molecular Diagnostics
Liquid Biopsy
Biomarker-based Companion Diagnostics
Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)

By Region:

North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait

Years Considered for the Study:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with country-level insights.
Competitive landscape featuring major players in the market.
Analysis of key business strategies and recommendations for future market expansion.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Pancreatic Cancer Precision Medicine Market Executive Summary

1.1. Global Pancreatic Cancer Precision Medicine Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Therapeutic Approach
- 1.3.2. By Diagnostic Technology
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Pancreatic Cancer Precision Medicine Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Pancreatic Cancer Precision Medicine Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising adoption of precision medicine and personalized treatments
- 3.1.2. Advancements in molecular diagnostics and genomic profiling
- 3.1.3. Increasing prevalence of pancreatic cancer and demand for targeted therapies
3.2. Market Challenges
- 3.2.1. High cost of precision medicine therapies and diagnostic tests
- 3.2.2. Regulatory complexities in drug approvals and reimbursement policies
3.3. Market Opportunities
- 3.3.1. Integration of AI-driven bioinformatics for treatment selection
- 3.3.2. Emerging clinical trials for novel precision therapies
- 3.3.3. Expansion of precision medicine in developing markets

Chapter 4. Global Pancreatic Cancer Precision Medicine Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Pancreatic Cancer Precision Medicine Market Size & Forecasts by Therapeutic Approach (2022-2032)

5.1. Segment Dashboard
5.2. Global Pancreatic Cancer Precision Medicine Market: Therapeutic Approach Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Targeted Therapy
  - PARP Inhibitors
  - Monoclonal Antibodies
  - Small Molecule Inhibitors (EGFR Inhibitors, KRAS Inhibitors)
- 5.2.2. Immunotherapy
  - Immune Checkpoint Inhibitors (PD-1 Inhibitors, PD-L1 Inhibitors)
  - Cancer Vaccines (GVAX, Algenpantucel-L)
  - Adoptive T-Cell Therapies (CAR-T Therapies)
- 5.2.3. Chemotherapy-Precision Combinations
- 5.2.4. Other Therapeutic Approaches

Chapter 6. Global Pancreatic Cancer Precision Medicine Market Size & Forecasts by Diagnostic Technology (2022-2032)

6.1. Segment Dashboard
6.2. Global Pancreatic Cancer Precision Medicine Market: Diagnostic Technology Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Genomic Testing
- 6.2.2. Molecular Diagnostics
- 6.2.3. Liquid Biopsy
- 6.2.4. Biomarker-based Companion Diagnostics
- 6.2.5. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)

Chapter 7. Global Pancreatic Cancer Precision Medicine Market Size & Forecasts by Region (2022-2032)

7.1. North America Pancreatic Cancer Precision Medicine Market
- 7.1.1. U.S.
- 7.1.2. Canada
- 7.1.3. Mexico
7.2. Europe Pancreatic Cancer Precision Medicine Market
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. France
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Denmark
- 7.2.7. Sweden
- 7.2.8. Norway
7.3. Asia Pacific Pancreatic Cancer Precision Medicine Market
- 7.3.1. Japan
- 7.3.2. China
- 7.3.3. India
- 7.3.4. Australia
- 7.3.5. South Korea
- 7.3.6. Thailand
7.4. Latin America Pancreatic Cancer Precision Medicine Market
- 7.4.1. Brazil
- 7.4.2. Argentina
7.5. Middle East & Africa Pancreatic Cancer Precision Medicine Market
- 7.5.1. South Africa
- 7.5.2. Saudi Arabia
- 7.5.3. UAE
- 7.5.4. Kuwait

Chapter 8. Competitive Intelligence

8.1. Key Company SWOT Analysis
- 8.1.1. AstraZeneca
- 8.1.2. Pfizer Inc.
- 8.1.3. Novartis AG
8.2. Top Market Strategies
8.3. Company Profiles
- 8.3.1. Amgen Inc.
- 8.3.2. F. Hoffmann-La Roche Ltd
- 8.3.3. Bayer AG
- 8.3.4. Eli Lilly and Company
- 8.3.5. Merck & Co., Inc.
- 8.3.6. Teva Pharmaceutical Industries Ltd
- 8.3.7. PharmaCyte Biotech, Inc.
- 8.3.8. Genentech, Inc.
- 8.3.9. Guardant Health
- 8.3.10. Illumina, Inc.

Chapter 9. Research Process

9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
9.2. Research Attributes